Posted on February 10, 2017 by Sitemaster
So apparently Prostate Cancer Canada has been working (rather secretively) on a series of projects under the umbrella name of their “True Nth” initiative. But it’s a little difficult to work out quite what is encompassed by this initiative, which has been funded (at least in part) by Movember. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: Canada, care, life, outcome, quality, True Nth | Leave a comment »
Posted on October 28, 2014 by Sitemaster
The Canadian Task Force on Preventive Health Care (CTFPHC) has just issued a guidance document that is not going to make most prostate cancer survivors very happy (either in Canada or elsewhere). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Canada, Diagnosis, risk, screening | 26 Comments »
Posted on May 29, 2013 by Sitemaster
According to a media release issued by Janssen, Inc. (a division of Johnson & Johnson) earlier today, Health Canada has approved the use of abiraterone acetate (Zytiga®) + prednisone for the treatment of chemotherapy-naive patients with asymptomatic or mildly symptomatic, metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, Canada, castration-resistant, chemotherapy-naïve, mCRPC, metastratic, Zytiga | Leave a comment »
Posted on August 1, 2011 by Sitemaster
According to a media release issued by Johnson & Johnson late last week, after a priority review, Health Canada has approved abiraterone acetate (Zytiga™) in combination with prednisone for the treatment of men with metastatic, castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone acetate, Canada, Zytiga | Leave a comment »
Posted on May 11, 2011 by Sitemaster
A new report has suggested that there will be a 201 percent increase in the annual number of prostate cancer diagnoses in Canada between 2009 and 2021. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: Canada, Diagnosis, incidence, mortality, risk | 1 Comment »
Posted on August 15, 2009 by Sitemaster
We now know how much it cost the Province of Ontario, in Canada, on average, to manage prostate cancer cases between 1995 and 2002. However, it is doubtful that these data would necessarily be applicable to the same time period in the USA or other nations. … READ MORE …
Filed under: Management | Tagged: Canada, cost | 2 Comments »
Posted on July 25, 2009 by Sitemaster
Today’s news reports address items on:
- The burden of prostate cancer in Canada
- Pelvic lymph node dissection and RALP
- Data from early trials of sipuleucel-T in advanced prostate cancer
- Implementation of osteoporosis screening guidelines in prostate cancer patients … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Canada, guidelines, incidence, mortality, osteoporesis, pelvic lymph node dissection, PLND, Provenge, screening, sipuleucel-T | 3 Comments »
Posted on August 16, 2008 by Sitemaster
There is in fact a good deal of news this weekend. Information about four items are provided below and we will discuss additional news items tomorrow. Items in this article include:
- The relative views of Canadian urologists and radiation oncologists toward PSA screening and treatments for localized disease
- A complex form of investigational immunotherapy for localized prostate cancer
- Data suggesting the possibility of a survival benefit resulting from treatment of hormone refractory prostate cancer patients with docetaxel (Taxotere) + ASA404 (an investigational drug)
- A new review of psychosocial issues and their impact on management of prostate cancer … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ASA404, Canada, cancer, immunotherapy, news, prostate, psychosocial issues, radio-oncologists, update, urologists, vaccine | Leave a comment »